Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -14K | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -13M | -5M | -4M | -944K |
| EBITDA | -12M | -16M | -5M | -4M | -755K |
| Net Income | -12M | -16M | -5M | -3M | -755K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.73
-5.86% today
Window Change
-44.40%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silexion Therapeutics Ltd. (SLXN) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.73 and down 44.4% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -239.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -239.4%, free cash flow -28.6% with operating margin 0.0% and ROIC -250.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLXN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLXN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLXN Max Drawdown
-45.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLXN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$755.2K
+76.5% YoY
Free Cash Flow
-$1.4M
+58.3% YoY
Revenue Growth
+0.0%
EPS Growth
-239.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -14K | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -13M | -5M | -4M | -944K |
| EBITDA | -12M | -16M | -5M | -4M | -755K |
| Net Income | -12M | -16M | -5M | -3M | -755K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 1M | 5M | 8M | 39K |
| Total Assets | 7M | 3M | 5M | 9M | 115M |
| Total Liabilities | 5M | 7M | 17M | 16M | 509K |
| Shareholder Equity | 3M | -4M | -15M | -11M | 115M |
| Total Debt | 468K | 4M | 171K | 271K | 0 |
| Net Debt | -6M | 3M | -4M | -8M | -39K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+57.8% YoY
Capital Expenditures
4
+100.0% YoY
Free Cash Flow
1M
+58.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-387.8%
Debt / Equity
0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.